{"filings":[{"id":1414716,"accession_number":"0001193125-26-294445","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2026-07-02T20:00:15+00:00","items":["7.01"],"status":"ready","headline":"CMS withdraws Medicare billing changes for Orthofix bone growth stimulators; reimbursement restored to prior rates","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On July 1, 2026, CMS issued revised guidance withdrawing May 18, 2026 billing changes for HCPCS codes E0747, E0748, E0760.","Orthofix expects average Medicare reimbursement for these codes to return to rates in effect prior to May 18, 2026.","The reversal follows FDA's April 16, 2026 reclassification of non-invasive bone growth stimulators from Class III to Class II.","The prior CMS changes had modified billing requirements and Medicare fee schedule treatment; now withdrawn."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":981956,"accession_number":"0001193125-26-266679","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2026-06-11T11:01:40+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Orthofix shareholders approve stock purchase plan share increase, elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved Amendment No. 5 to Stock Purchase Plan, increasing authorized shares by 1.25M to 6.1M.","All 10 director nominees elected; Burris (24.9M for, 5.2M against) and Paolucci (24.7M for, 5.4M against) had notable opposition.","Advisory vote on executive compensation passed with 24.5M for, 5.6M against (81.4% approval).","Ernst & Young ratified as independent auditor for FY 2026 with 33.3M votes in favor.","Meeting quorum of 34.8M shares (86% of outstanding) present from 40.4M eligible shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":564078,"accession_number":"0001193125-26-233429","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2026-05-21T12:00:44+00:00","items":["7.01"],"status":"ready","headline":"Orthofix cuts FY2026 guidance as CMS cuts bone stimulator reimbursement ~10%","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CMS reduced Medicare reimbursement for HCPCS codes E0747, E0748, E0760 by ~10% effective May 18, 2026.","FY2026 net sales guidance lowered to $838M-$848M; non-GAAP adjusted EBITDA to $90M-$93M.","Company no longer expects positive free cash flow in FY2026; three-year financial targets abandoned.","Further CMS changes could require additional outlook revisions; long-term impact still being evaluated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99434,"accession_number":"0001193125-26-204999","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Orthofix Q1 pro forma revenue $196.4M +2.7% constant currency; reaffirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss $(20.9)M vs $(53.1)M prior year; adjusted EBITDA $9.7M (4.9% of pro forma sales) vs $11.4M (6.0%) prior year.","Global Spine Fixation +6%, Therapeutic Solutions +5%, Limb Reconstruction +10% reported (+3% constant currency).","Reaffirms FY2026 net sales $850M-$860M, adjusted EBITDA $95M-$98M, positive free cash flow.","Cash $120.9M at March 31, 2026; plans to repay $424M 0.875% exchangeable notes due June 2026.","Distributor transitions largely behind; expects improved commercial execution and product launches later in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":196708000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99433,"accession_number":"0001193125-26-148853","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2026-04-09T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Orthofix reports prelim Q1 net sales $196.7M, realigns spine leadership, Reinhardt to depart","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q1 net sales $196.7M; reported constant currency +0.4%, pro forma constant currency +2.7% YoY.","FY 2026 guidance reaffirmed: net sales $850M-$860M, adj. EBITDA $95M-$98M, positive FCF ex-legal settlements.","President, Global Spine Max Reinhardt to depart on/about June 12, 2026; role eliminated in realignment.","Key spine leaders (Bannigan, Sienkiewicz, Winge) now report directly to CEO; Fisher expands to Biologics.","M6 disc discontinuation impact fell to $0.3M in Q1 from $4.4M in Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":196708000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115419,"accession_number":"0001193125-26-065184","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Orthofix Q4 net sales $219.9M, net loss narrows; FY26 guidance $850-860M sales, $95-98M adj. EBITDA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss $(2.2)M vs $(29.1)M YoY; adjusted EBITDA $29.2M (13.4% margin), up 230 bps.","Full-year 2025 net sales $822.3M (+2.9% reported); pro forma $811.9M (+4.1% constant currency).","FY25 net loss $(92.2)M, improved from $(126.0)M; free cash flow $3.1M (ex-M6 restructuring).","2026 guidance: net sales $850-860M (~5.5% pro forma CC growth); adj. EBITDA $95-98M.","Three-year targets (2026-28): 6.5-7.5% sales CAGR, mid-teens EBITDA margin by 2028, positive FCF."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":822312000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131835,"accession_number":"0001193125-25-263529","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Orthofix Q3 pro forma net sales up 5.7%; adj EBITDA margin expands to 12.1%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Pro forma net sales $203.4M, +5.7% constant currency vs Q3 2024; reported net sales $205.6M.","Non-GAAP adj EBITDA $24.6M (12.1% margin) vs $19.2M (9.8%) prior year; seven consecutive quarters of expansion.","U.S. Spine Fixation sales +8%, Bone Growth Therapies +6%, Global Orthopedics constant currency +6%.","FY2025 pro forma net sales guidance narrowed to $810-814M; adj EBITDA guidance raised low end to $84-86M.","Free cash flow positive $2.5M in Q3; positive FCF expected for full year 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":602401000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148428,"accession_number":"0000950170-25-102383","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Orthofix Q2 net sales $203.1M (+2.3%); adj. EBITDA $20.6M; positive FCF; reaffirms FY25 guide","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Pro forma net sales (ex-M6) $200.7M, +3.5% constant currency; net loss $(14.1)M vs $(33.4)M prior year.","Non-GAAP pro forma adjusted EBITDA $20.6M (10.3% margin), up 24% YoY; six straight quarters of margin expansion.","Free cash flow positive $4.5M in Q2; cash, equivalents and restricted cash $68.7M.","U.S. Spine Fixation sales +5% (volume +7%); BGT Fracture +7%; U.S. Orthopedics +28%.","FY2025 guidance reaffirmed: pro forma net sales $808-816M, adj. EBITDA $82-86M, positive FCF."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":396767000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167226,"accession_number":"0000950170-25-088194","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["5.07","8.01"],"status":"ready","headline":"Orthofix holds 2025 annual meeting; all director nominees elected, say-on-pay approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 10 board nominees elected; Vickie Capps received 29.66M votes for, 0.91M against.","Say-on-pay advisory resolution approved with 30.00M votes for (97.9% of votes cast).","Ratification of Ernst & Young as auditor passed with 35.02M votes for (99.0% of votes cast).","Board appointed Vickie L. Capps to both Audit & Finance and Compensation & Talent Development committees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167225,"accession_number":"0000950170-25-063953","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Orthofix Q1 net loss $53.1M; lowers FY2025 net sales guidance to $808-816M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 pro forma net sales $189.2M, up 4.3% constant currency YoY; GAAP net loss $53.1M ($1.35/share) vs $36.0M loss year ago.","Non-GAAP pro forma adjusted EBITDA $11.4M (6.0% margin), up 49% vs $7.7M in Q1 2024; adjusted gross margin 70.3%.","Lowered FY2025 net sales guidance to $808-816M (pro forma) from $818-826M; reaffirms adjusted EBITDA $82-86M and positive free cash flow.","U.S. Spine Fixation +4%, BGT +5%, Global Orthopedics constant currency +11% YoY; TrueLok Elevate TBT System received FDA clearance.","Management cites commercial channel optimization causing temporary softness; expects growth to normalize after distributor transitions."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":193646000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167224,"accession_number":"0000950170-25-051645","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2025-04-07T23:59:59+00:00","items":["1.01","1.02"],"status":"ready","headline":"Orthofix enters new 12.5-year Carlsbad lease with total cost $34.6M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New lease effective April 1, 2025 for Carlsbad office (5770 Armada Drive); term through Oct 31, 2037.","Monthly rent includes 3.5% annual increases; total pre-tax occupancy cost estimated $34.6M.","Company also responsible for real estate taxes, insurance, utilities, and other expenses.","Prior sublease terminated as of April 1, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184577,"accession_number":"0000950170-25-037630","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2025-03-12T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Orthofix appoints Vickie Capps to board of directors, effective March 11, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Capps is a CPA and former CFO of DJO Global; brings expertise in global ops, business development, and corporate finance.","Board size increased from 9 to 10 directors; Capps will serve as an independent director.","Capps currently serves on boards of Amedisys, Janux Therapeutics, Enable Injections, and Breg.","No transactions requiring Item 404(a) disclosure; standard director indemnification agreement to be entered.","Capps to participate in non-employee director compensation program; committee assignments to be determined later."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184576,"accession_number":"0000950170-25-026062","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Orthofix reports record Q4 net sales of $215.7M (+8% YoY); guides FY25 sales $818-826M, adj. EBITDA $82-86M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $215.7M (+8% YoY); record BGT $63.9M (+9%) and Global Orthopedics $35.8M (+18% cc).","Q4 net loss $(29.1)M ($(0.75)/share); adjusted EBITDA $23.9M (11.1% margin) vs $19.6M (9.8%) in Q4 2023.","FY24 net sales $799.5M (+7%); net loss $(126.0)M vs $(151.4)M; adjusted EBITDA $67.4M (8.4% margin) vs $46.3M.","Discontinuing M6 artificial disc lines ($23.4M 2024 sales); guides FY25 sales $818-826M (ex-M6, +6.5% cc) and adj. EBITDA $82-86M.","Long-term CAGR target raised to 6.5-7.5%; Q4 free cash flow $15.2M; cash $85.7M at year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":799491000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201149,"accession_number":"0000950170-24-124165","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"Orthofix enters $275M secured credit facility with Oxford Finance; repays Blue Torch loan","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New credit agreement provides $160M term loan, $65M delayed draw, and up to $50M discretionary facility, maturing Nov 2029.","Interest rate: greater of 8.75% or 5.75% plus 1-month SOFR; facility fee 1.5% of each funded tranche.","Company terminated prior $275M credit agreement with Blue Torch Finance dated Nov 2023.","Covenants require min $45M unrestricted cash at closing, $15M ongoing, and max 4.0x total debt-to-EBITDA leverage.","Delayed draw Term B available from Jan 2025 to Jun 2026 subject to leverage compliance; Term C at Oxford's discretion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201148,"accession_number":"0000950170-24-122777","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Orthofix Q3 net sales $196.6M (+7%), adjusted EBITDA $19.2M, introduces 2027 targets","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $196.6M, +7% YoY; U.S. Spine Fixation +18%, U.S. Orthopedics record quarter +15%.","Net loss $(27.4)M vs $(28.9)M prior year; adjusted EBITDA $19.2M, margin 9.8% vs 7.3%.","Free cash flow positive $5.9M in Q3; new $275M credit facility announced.","Reiterates FY2024 guidance: net sales $795-800M, adjusted EBITDA $64-69M.","Introduces 2027 targets: 6-7% revenue CAGR, mid-teens adjusted EBITDA margin, positive FCF."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":583834000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217172,"accession_number":"0000950170-24-091199","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Orthofix Q2 net sales $198.6M (+6% YoY); raises FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net sales $198.6M, +6% YoY; net loss $(33.4M) vs $(39.4M) prior year; EPS $(0.88).","Non-GAAP adjusted EBITDA $16.6M (8.4% margin), +310 bps YoY from $9.9M.","Bone Growth Therapies +12% YoY; U.S. Spine Fixation +12% YoY; Global Orthopedics +5%.","FY2024 net sales guidance raised to $795-800M; adjusted EBITDA to $64-69M.","Expects positive free cash flow in H2 2024; appointed four new executive team members."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":387228000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236954,"accession_number":"0000950170-24-075288","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Orthofix President of Global Orthopedics departing; shareholders approve 5M share LTIP increase","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kimberley A. Elting, President Global Orthopedics, departing on or about July 5, 2024; will receive severance and accelerated vesting.","Shareholders approved Amendment No. 5 to LTIP, increasing shares reserved by 5,000,000 to 16,275,000 total.","Shareholders approved Amendment No. 4 to Stock Purchase Plan, increasing shares by 1,250,000 to 4,850,000 total.","Michael M. Finegan appointed Chair of the Board; remaining committee chairs also appointed effective June 18, 2024.","All eight director nominees elected; advisory vote on executive compensation passed with 96.8% support."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236953,"accession_number":"0000950170-24-053961","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Orthofix Q1: net sales $188.6M (+7.7%), net loss narrows to $36M; raises FY sales outlook to $790-795M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $188.6M, +7.7% YoY; Bone Growth Therapies +10%, U.S. Spine Fixation +16%, U.S. Orthopedics +23%.","GAAP net loss $(36.0)M ($0.95 loss per share) vs $(60.9)M ($1.71) prior year; adjusted EBITDA $7.7M (4.1% of sales).","FY2024 net sales guidance raised to $790-795M (from $785-795M); adjusted EBITDA guidance reaffirmed at $62-67M.","Cash and cash equivalents $29.5M; $125M drawn on $150M credit facility."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":188608000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236952,"accession_number":"0000950170-24-046161","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2024-04-22T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Orthofix amends cooperation pact with Engine Capital over fiduciary duty carve-outs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to Dec 2023 cooperation agreement with Engine Capital clarifies Board fiduciary duties override certain obligations.","Board may decline to recommend/support Specified Directors (Bazaar, Finegan, Kummeth) without breaching agreement.","If Board exercises fiduciary duty, Engine Group can solicit proxies for those directors and standstill provisions lift.","Amendment also subjects other company obligations (e.g., committee appointments, board size) to fiduciary duty."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236951,"accession_number":"0000950170-24-044082","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2024-04-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Three Orthofix directors to leave board at 2024 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stuart M. Essig and James F. Hinrichs elected not to stand for re-election at June 2024 annual meeting.","Catherine M. Burzik confirmed she will not stand, consistent with November 2023 announcement.","Departures are not due to any disagreement with the company's operations, policies or practices.","All three will continue to serve on the board until the annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254543,"accession_number":"0000950170-24-025867","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2024-03-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Orthofix Q4 net sales $200.4M (+7% pro forma constant currency); FY24 guidance implies 5-7% growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $200.4M; Bone Growth Therapies up 15% YoY; U.S. spine fixation up 13.5%.","Q4 net loss $(22.2)M ($(0.59)/share); Non-GAAP adjusted EBITDA $19.6M (9.8% of sales), up 96% YoY pro forma.","Full-year 2023 net sales $746.6M; net loss $(151.4)M; adjusted EBITDA $46.3M (6.2% of sales), up 69%.","FY24 guidance: net sales $785M-$795M (5-7% constant currency growth); adjusted EBITDA $62M-$67M; exit Q4 FCF positive.","Achieved $32M in annualized merger-related synergies; cash $37.8M, $100M drawn on $150M credit facility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254542,"accession_number":"0000950170-24-005068","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2024-01-17T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Orthofix appoints Julie Andrews as CFO with inducement stock awards and severance agreement","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Julie Andrews started as CFO on Jan 15, 2024; previously CFO at Smart Wires and SVP Finance at Wright Medical.","Received inducement grants: performance-based RSUs for 65,934 shares (at target), time-based RSUs for 32,967 shares, and options for 76,878 shares.","Severance equal to 1.0x base salary + target bonus (1.5x on change in control) plus COBRA reimbursement for up to 12 months.","Options vest when service conditions met and stock price averages 150% of grant date price over one month.","Interim CFO Geoffrey Gillespie thanked; company expects Andrews to help drive growth and shareholder value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254541,"accession_number":"0000950170-24-003420","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2024-01-09T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Orthofix names new CEO and CFO; Q4 net sales $200.3M, pro forma up 7.5%","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Massimo Calafiore appointed CEO, effective Jan 8, 2024; received $7.5M in inducement equity awards (RSUs + options).","Julie Andrews named CFO, effective Jan 15; base salary $475K, target bonus 70%, sign-on equity $1.8M.","Kevin Kenny departed as officer Jan 8; eligible for severance and $500/hr consulting for 12 months.","Q4 preliminary net sales $200.3M, +63.8% reported (+7.5% pro forma); BGT up 15.3%.","Full-year 2023 net sales $746.5M, +62% reported (+6.5% pro forma)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254540,"accession_number":"0000950170-24-002924","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Massimo Calafiore begins as Orthofix CEO immediately; Julie Andrews named CFO effective Jan 15","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Massimo Calafiore assumes role of President and CEO effective immediately and joins the Board of Directors.","Julie Andrews appointed CFO effective January 15, 2024; previously CFO at Smart Wires Technology and SVP Finance at Wright Medical.","Catherine Burzik, who served as interim CEO, steps down from that role but remains Chair of the Board.","Appointments fill key leadership roles following a search that attracted many highly qualified candidates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272020,"accession_number":"0000950170-23-070740","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2023-12-15T23:59:59+00:00","items":["1.01","5.02","8.01","9.01"],"status":"ready","headline":"Orthofix enters cooperation agreement with Engine Capital; appoints three new directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Engine Capital, holder of ~8.2% of OFIX shares, and Orthofix enter cooperation agreement.","Board expands from 8 to 11, appoints Alan Bazaar, Michael Finegan, Charles Kummeth as new independent directors.","Strategy Committee formed; three current directors will not stand for re-election at 2024 Annual Meeting; board size to reduce to nine.","Engine group subject to standstill, voting commitments, and capped at 9.9% ownership during agreement term.","Perella Weinberg Partners and Hogan Lovells advise Orthofix; Olshan Frome Wolosky advises Engine."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272019,"accession_number":"0000950170-23-067364","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2023-12-01T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Orthofix names Massimo Calafiore as President and CEO; Burzić not standing for re-election","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Massimo Calafiore appointed President and CEO effective early 2024, following LimaCorporate's acquisition by Enovis.","Calafiore receives $825k base salary, 110% target bonus, and $7.5M in equity inducement awards (50% performance RSUs, 25% options, 25% time RSUs).","He will receive a $225k after-tax relocation payment to San Diego area.","Interim CEO Catherine Burzić will not stand for re-election at 2024 Annual Meeting; remains Chair until then."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272018,"accession_number":"0000950170-23-061122","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Orthofix Q3 net sales $184M (+61% reported, +8% pro forma); GAAP EPS -$0.77, adj. $0.07","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $184M, +61% reported, +8% pro forma (excl. one-time stocking order); Bone Growth Therapies +15%.","GAAP net loss $28.9M ($0.77/share); adjusted net income $2.7M ($0.07/share); adjusted EBITDA $13.5M (7.3% of sales).","Entered new $150M financing agreement (Nov 6, 2023), replaced prior $175M revolver; cash $33.7M at Sep 30.","Updated 2023 net sales guidance lowered to $739M-$744M (prev $752M-$758M); adjusted EBITDA guidance unchanged $42M-$46M.","Management transition: Catherine Burzik (Chair) as Interim CEO after board investigation led to departure of three former executives."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":546226000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272017,"accession_number":"0000950170-23-061099","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"Orthofix enters $150M credit facility with Blue Torch; repays prior $175M revolver","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $100M term loan plus $25M delayed draw and $25M revolver, maturing Nov 6, 2027.","Borrowings bear interest at SOFR+7.25% or base+6.25%; 2.00% unused revolver fee.","Financing used to repay all amounts under the prior $175M JPMorgan credit agreement.","Covenants include minimum liquidity, maximum consolidated leverage ratio, minimum asset coverage."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272016,"accession_number":"0000950170-23-052018","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2023-10-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Orthofix board member Keith Valentine resigns; interim CEO gets $825k base, $1.5M RSUs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Keith C. Valentine resigns from Board; notes disagreement with termination for cause of Valentine and others on Sept 11.","Board reduces size from nine to eight directors effective immediately.","Interim CEO Burzik receives $825k base salary, 110% bonus target, $100k after-tax cash bonus for relocation.","Burzik granted $1.5M RSUs vesting 90 days after a successor CEO assumes office."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272015,"accession_number":"0000950170-23-051671","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2023-10-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Orthofix sets compensation for Interim CFO Gillespie with $290k base, stipend, and severance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Interim CFO Geoffrey Gillespie receives updated base salary of $290,000 and target bonus of 70% of base salary.","Monthly stipend of $12,500 during service as Interim CFO.","Grant of RSUs with fair market value $290,000 vesting fully on second anniversary.","Severance agreement: if terminated without cause or for good reason, receives pro-rata bonus and severance equal to base salary plus target bonus."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288864,"accession_number":"0001193125-23-234766","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2023-09-14T23:59:59+00:00","items":["5.02","7.01","8.01","9.01"],"status":"ready","headline":"Orthofix terminates CEO, CFO, CLO for misconduct; appoints interim replacements","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Keith Valentine, John Bostjancic, Patrick Keran fired for cause after investigation found repeated inappropriate and offensive conduct.","Catherine Burzik (Board Chair) named Interim CEO; Geoffrey Gillespie (VP Corp Controller) Interim CFO; Puja Leekha (Chief Ethics & Compliance) Interim CLO.","Company states misconduct unrelated to strategy, results, or previously filed financial statements.","Board will immediately search for permanent successors; created Executive Committee with broad authority.","Morgan Stanley conference participation on Sep 13 canceled; investor day planned for Sep 20 postponed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288863,"accession_number":"0000950170-23-039871","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Orthofix Q2 2023 revenue $187M (+7% pro forma), raises FY adjusted EBITDA guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $187.0M, up 58% reported / 7% pro forma constant currency YoY.","GAAP EPS $(1.07); adjusted EPS $0.02; adjusted EBITDA $9.9M (5.3% margin).","Bone Growth Therapies grew 10.3% YoY; U.S. spine implants +7% pro forma.","FY23 net sales guidance raised to $752-758M; adjusted EBITDA to $42-46M.","Full commercial launch of WaveForm A interbody and TrueLok Phantom/Tornado hinges."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":362220000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309552,"accession_number":"0000950170-23-029063","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2023-06-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Orthofix enters enhanced severance agreements with CEO, CFO, and three other officers","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Valentine gets 1.5x salary+target bonus severance (2.99x in CiC period through Jan 2025); other executives get 1.0x (1.5x in CiC).","SeaSpine merger (Jan 5, 2023) triggers CiC period running through Jan 4, 2025 for all agreements.","COBRA reimbursement: up to 18 months for CEO; up to 12 months for other executives; equity awards get partial/full acceleration.","Agreements supersede prior employment agreements (Valentine), SeaSpine retention plan (Bostjancic, Keran), and prior severance deals (Elting, Kenny).","No minimum compensation guaranteed; benefits conditioned on signing release and compliance with non-compete/solicitation covenants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309551,"accession_number":"0000950170-23-028907","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2023-06-20T23:59:59+00:00","items":["5.02","5.07","5.03","7.01","8.01","9.01"],"status":"ready","headline":"Orthofix shareholders approve doubling authorized shares and board changes: Serbousek out, Burris returns","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved increase in authorized common shares from 50M to 100M; officer exculpation and forum selection added.","LTIP shares increased by 2.9M and SPP by 750K, both approved by stockholders.","Bylaws amended for universal proxy rules, enhanced disclosure, and removal of prior forum selection.","Jon Serbousek did not stand for re-election; Catherine Burzik reappointed Chair; Wayne Burris rejoined board, assigned to Audit and Compliance committees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309550,"accession_number":"0000950170-23-028350","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2023-06-15T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Orthofix cuts credit facility to $175M, amends EBITDA addbacks","summary_kind":"llm","event_type":"debt","confidence":"medium","bullets":["Credit facility reduced from $300M to $175M; interest rate increased in certain circumstances.","Maturity unchanged at October 25, 2024; $51M currently outstanding.","Amended EBITDA calculation allows certain expense addbacks and higher foreign subsidiary EBITDA share from Q1 2023.","Orthofix pledged ownership interest in Italian subsidiary Orthofix S.r.l. as additional collateral."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309549,"accession_number":"0000950170-23-019696","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Orthofix Q1 net sales $175.2M (+65% reported, +12% pro forma CC); GAAP EPS $(1.71), adj. EPS $(0.10)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $60.9M vs. $4.5M loss prior year; adjusted net loss $3.6M vs. adj. net income $1.0M.","U.S. spinal implant pro forma sales +18% YoY; Bone Growth Therapies +14%; Global Orthopedics +13.6% CC.","Full commercial launch of Lattus Lateral Access System and Fathom Pedicle Retractor System announced.","FY 2023 net sales guidance raised to $750-756M (from $743-753M); adj. EBITDA expected $40-45M.","Cash $50.0M; $45M drawn on $300M revolver; free cash flow $(45.9)M for Q1."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":175204000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309548,"accession_number":"0000950170-23-012209","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2023-04-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Orthofix Medical updates compensation for President Global Spine Kevin Kenny","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Base salary raised to $495,000, retroactive to Jan 5, 2023 merger close.","Target 2023 annual cash bonus set at 70% of base salary.","Granted $125,000 in time-based RSUs and $125,000 in stock options, vesting over 3 years.","Performance-based RSUs of $100,000 tied to 2023 Global Spine financial metrics.","Amended Jan 2023 equity grants to 3-year vesting; potential $100,000 one-time cash bonus."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328260,"accession_number":"0000950170-23-007437","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Orthofix confirms no exposure to failed Silicon Valley Bank","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company holds no deposits, securities, or accounts at SVB.","$300M secured revolving credit facility is with JPMorgan Chase; SVB not a lender.","Disclosure follows SVB closure by California regulators on March 10, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328259,"accession_number":"0000950170-23-006239","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2023-03-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Orthofix reports Q4 2022 results; SeaSpine merger closed Jan 5; combined 2023 guidance $743-753M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Orthofix stand-alone Q4 net sales $122.2M (-2% reported, flat constant currency); net loss $7.1M vs $32.8M loss prior year.","SeaSpine stand-alone Q4 net sales $63.4M (+14% YoY); net loss $19.0M vs $18.8M loss prior year.","Combined company expects Q1 2023 net sales $166-170M and full-year 2023 net sales $743-753M.","Merger of Orthofix and SeaSpine completed January 5, 2023; results do not include merger accounting adjustments.","Orthofix borrowed $45M under credit facility in Jan/Mar 2023 to fund merger expenses and working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328255,"accession_number":"0000950170-23-002508","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K/A","filed_at":"2023-02-13T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Orthofix files SeaSpine audited FY2021 financials: revenue $191.5M, net loss $54.3M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["SeaSpine 2021 revenue $191.5M (+24% YoY); operating loss $61.0M.","Net loss $54.3M in 2021 vs $43.2M in 2020; diluted EPS loss $1.62.","SeaSpine acquired 7D Surgical in May 2021 for $120.6M, adding $84.6M goodwill.","Pro forma combined Orthofix+SeaSpine financials filed as Exhibit 99.3 (not detailed in this excerpt).","Merger of Orthofix and SeaSpine completed Jan 5, 2023; this amendment supplies required financials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328258,"accession_number":"0000950170-23-000431","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Orthofix reports Q4 net sales $122.2M (-2% YoY); SeaSpine Q4 $63.2-63.7M (+13%+); merger closed Jan 5","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Orthofix Q4 net sales $122.2M, down ~2% YoY; constant currency flat; Bone Growth Therapies up ~3%.","SeaSpine Q4 net sales $63.2-63.7M, up >13% YoY; U.S. Spinal Implants +23%, U.S. Orthobiologics +19%.","Full-year: Orthofix $460.7M (-0.8% as reported); SeaSpine ~$237.6M (+24% YoY).","Cash: Orthofix $51M; SeaSpine $29M; Orthofix borrowed $30M on revolver for merger expenses.","Merger of equals completed Jan 5; SeaSpine shareholders receiving 0.4163 OFIX shares per share."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.98,"consensus_revenue_estimate":null,"consensus_revenue_actual":460713000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328257,"accession_number":"0001193125-23-001900","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2023-01-05T23:59:59+00:00","items":["1.02","2.01","2.03","5.02","8.01","9.01"],"status":"ready","headline":"Orthofix completes merger with SeaSpine; Valentine named President and CEO","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger effective Jan 5, 2023; SeaSpine shareholders receive 0.4163 Orthofix shares per SeaSpine share (~16M shares).","Keith Valentine (former SeaSpine CEO) appointed Orthofix President and CEO; Jon Serbousek becomes Executive Chairman.","Combined company has ~1,600 employees, products in 68 countries; trades as OFIX on Nasdaq.","Board adds four new directors from SeaSpine (Essig, Henneman, Maniar, Valentine); four Orthofix directors resign.","SeaSpine credit agreement repaid and terminated; inducement plan for SeaSpine employees (1.33M shares reserved)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328256,"accession_number":"0001193125-23-001527","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2023-01-04T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Orthofix shareholders approve stock issuance for SeaSpine merger","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["17.1M votes for (97.7% of votes cast); 264k against, 131k abstain.","Issuance of Orthofix common stock to SeaSpine stockholders as part of Oct 10, 2022 merger agreement.","Special meeting quorum achieved with 87.54% of 20.0M outstanding shares represented.","Proposal to adjourn meeting not needed because sufficient votes were cast."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345926,"accession_number":"0001193125-22-312734","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2022-12-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Orthofix supplements SeaSpine merger disclosures with updated DCF and synergy projections","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Perella Weinberg DCF analyses updated: discount rates 9.75%-10.75%, perpetuity growth 3.0% for synergies.","SeaSpine standalone DCF range $2.93-$6.52 per share vs implied merger consideration $7.64 (Piper Sandler).","Orthofix standalone DCF range $18.15-$30.17 vs Orthofix closing price $18.34.","Piper Sandler fee estimated ~$4.3M contingent on deal closing; $1M opinion fee already paid.","Projected cost synergies: $42M in 2025E, rising to $50M in 2031E; stock-based comp synergies $8M in 2025E."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345925,"accession_number":"0001193125-22-298551","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2022-12-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Orthofix board rejects revised $24/share unsolicited PE bid, reaffirms SeaSpine merger","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Received unsolicited PE bid at $23/share, later revised to $24/share cash, subject to due diligence and financing.","Board unanimously determined revised offer is not reasonably likely to lead to a superior proposal to SeaSpine merger.","Board reaffirms recommendation for pending stock-for-stock merger with SeaSpine.","Special meeting of Orthofix stockholders set for Jan 4, 2023 to vote on SeaSpine merger approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345924,"accession_number":"0001193125-22-295519","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2022-11-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Orthofix receives unsolicited $23/share buyout bid, board reaffirms SeaSpine merger","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Received unsolicited non-binding indication from two PE sponsors to acquire Orthofix for $23 per share cash.","Board determined bid is not reasonably likely to lead to a superior proposal under SeaSpine merger agreement.","Board reaffirms recommendation for all-stock SeaSpine merger; Orthofix stockholders to own ~56.5% of combined firm.","Special stockholder meeting scheduled for Jan 4, 2023 to vote on stock issuance for SeaSpine merger.","SeaSpine merger expected to close early Q1 2023, subject to approvals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345923,"accession_number":"0001193125-22-289289","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2022-11-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Orthofix and SeaSpine name leadership team for combined company; John Bostjancic as CFO","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger of equals expected to close Q1 2023, subject to shareholder approvals.","John Bostjancic (SeaSpine CFO/COO) to serve as CFO of combined company post-closing.","Keith Valentine (SeaSpine CEO) to be CEO; Jon Serbousek (Orthofix CEO) to be Executive Chairman.","Full Executive Leadership Team announced, including presidents for orthopedics, spine, biologics, enabling technologies.","Doug Rice (Orthofix CFO) will assist with integration transition after close."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345922,"accession_number":"0000950170-22-021534","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Orthofix Q3: net sales $114M, GAAP EPS ($0.53); FY22 adj. EBITDA guidance cut; SeaSpine merger","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $114.0M, up 1% reported, 5% constant currency; Global Orthopedics grew 19% constant currency.","GAAP EPS ($0.53) vs ($0.11) prior year; adjusted EPS $0.13 vs $0.10.","Net loss widened to $10.7M from $2.2M; adjusted net income $2.7M.","FY2022 guidance lowered: net sales $457-463M, adjusted EBITDA $52-54M (from $53-57M), adjusted EPS $0.40-0.50 (from $0.45-0.55).","Announced agreement to merge with SeaSpine in all-stock merger of equals on October 11, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":338484000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345921,"accession_number":"0001193125-22-260160","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2022-10-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Orthofix reports Q3 preliminary net sales $114M, up 5% CC; announces SeaSpine merger","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q3 net sales $114M, +1% reported, +5% constant currency YoY; nine-month net sales $339M, flat reported.","Global Orthopedics grew 19% CC; Biologics +8% CC; Bone Growth Therapies +3% CC; Spinal Implants -7% CC.","Preliminary cash, cash equivalents and restricted cash ~$52M as of Sep 30, 2022.","Entered all-stock merger of equals with SeaSpine (NASDAQ: SPNE) to create leading spine and orthopedics company."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":338484000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345920,"accession_number":"0001193125-22-260149","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2022-10-11T23:59:59+00:00","items":["1.01","5.03","8.01","9.01"],"status":"ready","headline":"Orthofix and SeaSpine combine in all-stock merger of equals; 0.4163 exchange ratio, ~$693M pro forma revenue","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["SeaSpine shareholders to receive 0.4163 Orthofix shares per SPNE share; combined ownership 56.5% Orthofix, 43.5% SeaSpine.","Pro forma revenue ~$693M (trailing twelve months ended Sep 30, 2022); combined company has ~1,600 employees in 68 countries.","Jon Serbousek (Orthofix CEO) to be Executive Chairman; Keith Valentine (SeaSpine CEO) to be President and CEO.","Transaction expected to be adjusted EBITDA accretive by second year post-close; requires stockholder and antitrust approvals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-10-11T23:59:59+00:00|345920"}